{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:18:09Z","timestamp":1759335489707},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":746,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.jval.2011.05.032","type":"journal-article","created":{"date-parts":[[2011,8,13]],"date-time":"2011-08-13T16:31:52Z","timestamp":1313253112000},"page":"S39-S42","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S","title":["Costo Efectividad de Posaconazol versus Fluconazol\/Itraconazol en el Tratamiento Profil\u00e1ctico de las Infecciones F\u00fangicas Invasivas en M\u00e9xico"],"prefix":"10.1016","volume":"14","author":[{"given":"Kely","family":"Rely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre K.","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo Salinas","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2011.05.032_bib1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jval.2011.05.032_bib2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1086\/655683","article-title":"Epidemiology of opportunistic fungal infections in Latin America","volume":"51","author":"Nucci","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2011.05.032_bib3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1309\/AJCPRAAE8LZ7DTNE","article-title":"Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: a retrospective study of 1,630 autopsies performed between 1984 and 2002","volume":"132","author":"Antinori","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jval.2011.05.032_bib4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jiph.2010.07.005","article-title":"Profile of opportunistic infections in HIV-infected patients at a tertiary care center in Lebanon","volume":"3","author":"Naba","year":"2010","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jval.2011.05.032_bib5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.idc.2010.01.002","article-title":"Fungal infections in transplant and oncology patients","volume":"24","author":"Person","year":"2010","journal-title":"Infect Dis Clin North Am"},{"issue":"8 Suppl.","key":"10.1016\/j.jval.2011.05.032_bib6","doi-asserted-by":"publisher","first-page":"S380","DOI":"10.1097\/CCM.0b013e3181e6cf25","article-title":"Recognition and prevention of nosocomial invasive fungal infections in the intensive care unit","volume":"38","author":"Smith","year":"2010","journal-title":"Crit Care Med"},{"issue":"Suppl. 1","key":"10.1016\/j.jval.2011.05.032_bib7","first-page":"S21","article-title":"Infectious complications in neutropenic cancer patients","volume":"5","author":"Menichetti","year":"2010","journal-title":"CIntern Emerg Med"},{"key":"10.1016\/j.jval.2011.05.032_bib8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/01.CCM.0000201897.78123.44","article-title":"Invasive candidiasis in the intensive care unit","volume":"34","author":"Ostrosky-Zeichner","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jval.2011.05.032_bib9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1086\/380796","article-title":"Guidelines for treatment of candidiasis","volume":"38","author":"Pappas","year":"2004","journal-title":"Clinl Infect Dis"},{"key":"10.1016\/j.jval.2011.05.032_bib10","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1086\/322653","article-title":"A randomized, double-blind, double dummy, multicenter trial of voriconaloze andl fluconazole in the treatment of esophageal candidiasis in imnmunocompromised patients","volume":"33","author":"Ally","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2011.05.032_bib11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2011.05.032_bib12","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jval.2011.05.032_bib13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cncr.11479","article-title":"Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B","volume":"98","author":"Kontoyiannis","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2011.05.032_bib14","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.2165\/00003495-200363200-00008","article-title":"Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis","volume":"63","author":"Keating","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.jval.2011.05.032_bib15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. Fluconazole or Itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2011.05.032_bib16","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.clinthera.2007.09.015","article-title":"Posaconazole: an extended-spectrum triazole antifungal agent","volume":"29","author":"Schiller","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2011.05.032_bib17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2011.05.032_bib18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1600-0609.2008.01141.x","article-title":"Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands","volume":"81","author":"Stam","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jval.2011.05.032_bib19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00019053-200523050-00010","article-title":"Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia","volume":"23","author":"Dalziel","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2011.05.032_bib21","first-page":"241","article-title":"Tratamiento antimic\u00f3tico emp\u00edrico de pacientes inmunocomprometidos con neutropenia y fiebrepersistente con sospecha de aspergilosis sist\u00e9mica: an\u00e1lisis de costo-efectividad en M\u00e9xico","volume":"66","author":"Mould","year":"2009","journal-title":"Bol Med Hosp Infant Mex"},{"key":"10.1016\/j.jval.2011.05.032_bib22","series-title":"Farmacoeconom\u00eda: evaluaci\u00f3n econ\u00f3mica de los medicamentos","article-title":"Evaluaci\u00f3n econ\u00f3mica aplicada a los medicamentos: caracter\u00edsticas y metodolog\u00eda","author":"Anto\u00f1anzas","year":"1995"},{"key":"10.1016\/j.jval.2011.05.032_bib23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/027298902400448867","article-title":"Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease","volume":"22","author":"Briggs","year":"2002","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2011.05.032_bib24","series-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada","year":"2006"},{"key":"10.1016\/j.jval.2011.05.032_bib25","series-title":"Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee","year":"2007"},{"key":"10.1016\/j.jval.2011.05.032_bib26","series-title":"Propuesta de gu\u00edas para la conducci\u00f3n de estudios de evaluaci\u00f3n econ\u00f3mica como parte de la actualizaci\u00f3n de los cuadros b\u00e1sico de insumos para la salud","year":"2007"},{"key":"10.1016\/j.jval.2011.05.032_bib27","article-title":"Economic evaluation of posaconazol vs standard azole therapy in the prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada","volume":"11","author":"Tahami","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2011.05.032_bib28","series-title":"Cost-effectiveness of posaconazole versus standard azole treatment (fluconazole or itraconazole) in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain","author":"Grau","year":"2008"},{"key":"10.1016\/j.jval.2011.05.032_bib29","unstructured":"Greiner RA. Meier Y. O'Sullivan A. Imhof A. Cost-effectiveness of posaconazole versus standard azole therapy for the prevention of invasive fungal infections in high-risk patients in Switzerland. 34th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), March 30-April 2, 2008, Florence, Italy."},{"key":"10.1016\/j.jval.2011.05.032_bib30","series-title":"Pharmaco-economic analyis of posaconazole versus standard azole prophylaxis in high-risk neutropenic AML\/MDS patients in Germany","author":"Thalheimer","year":"2008"},{"key":"10.1016\/j.jval.2011.05.032_bib31","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1524-4733.2008.00486.x","article-title":"Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the U.S","volume":"12","author":"O'Sullivan","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2011.05.032_bib32","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.2146\/ajhp070588","article-title":"Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia","volume":"65","author":"Collins","year":"2008","journal-title":"Am J Health Syst Pharm"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301511014483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301511014483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T15:23:51Z","timestamp":1543591431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301511014483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1098301511014483"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2011.05.032","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}